Dysplastic colon tissue

Dysplastic colon tissue refers to an area of the colonic mucosa where cells exhibit abnormal growth and morphological changes, serving as a histological precursor to colorectal adenocarcinoma (PubMed: 25638808). This condition is characterized by cellular atypia, loss of architectural organization, and increased mitotic activity, often arising in the context of adenomatous polyps or chronic inflammatory bowel disease (NIH: StatPearls - Colon Polyps). While not a single molecular target, dysplastic tissue is the site of numerous genetic and epigenetic alterations, such as mutations in the APC, KRAS, and TP53 genes (UniProt: P04637). These molecular changes drive the transition from normal epithelium to a precancerous state and eventually to invasive malignancy. Therapeutic strategies focus on the endoscopic removal of dysplastic lesions or the use of chemopreventive agents to inhibit the progression to invasive cancer (PubMed: 11719171). For example, non-steroidal anti-inflammatory drugs (NSAIDs) like Celecoxib are used to reduce the number of adenomatous polyps in patients with familial adenomatous polyposis. Monitoring and identifying specific molecular markers within this tissue are critical for early detection and risk stratification in patients at high risk for colorectal cancer. The identification of dysplasia remains the gold standard for determining the need for surgical intervention or intensified surveillance in clinical practice.

Other names

Colonic dysplasiaPrecancerous colonic epitheliumAdenomatous dysplasia

Not applicable as this is a pathological tissue state; drugs used in this context typically target specific enzymes like COX-2 or inflammatory pathways to prevent progression to malignancy (PubMed: 11719171).